10.20.26 -- Build Smarter Cell And Gene Therapy Development Programs

High-quality cell sourcing combines diverse donors, precise matching, and efficient logistics for consistent material. Global delivery supports scalable, compliant workflows.

Advanced AAV analytics use high‑resolution multiplex platforms to assess genome integrity and capsid traits, improving accuracy, speeding development, and supporting regulatory quality control.

A single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how solutions support market entry and growth.

Explore the building blocks of plasmid manufacturing capability, highlighting how one approach supports AAV programs by helping manage production costs while maintaining high productivity.

Cell-free synthetic DNA templates can match or exceed plasmid-derived AAV titers while using less DNA, and they remove backbone sequences that plasmid-based production can package into the capsid.

Uncover the benefits of the Lentiviral vector (LVV) expansion to our AGCellerate program, designed to deliver GMP material for clinical trials in an accelerated timeline.

Integrated CRISPR workflows unify editing tools, manufacturing, and regulatory support, reducing risk and complexity while speeding a consistent path from research to clinic.

View genome engineering platforms that enable precise cell-line development, gene insertion, and genomic modification, accelerating therapeutic development while improving efficiency, consistency, and scalability.